<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36469401</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1520-4804</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>24</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>22</Day></PubDate></JournalIssue><Title>Journal of medicinal chemistry</Title><ISOAbbreviation>J Med Chem</ISOAbbreviation></Journal><ArticleTitle>Discovery of Potent and Selective Dual Leucine Zipper Kinase/Leucine Zipper-Bearing Kinase Inhibitors with Neuroprotective Properties in In Vitro and In Vivo Models of Amyotrophic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>16290</StartPage><EndPage>16312</EndPage><MedlinePgn>16290-16312</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.jmedchem.2c01056</ELocationID><Abstract><AbstractText>Dual leucine zipper kinase (DLK) and leucine zipper-bearing kinase (LZK) are regulators of neuronal degeneration and axon growth. Therefore, there is a considerable interest in developing DLK/LZK inhibitors for neurodegenerative diseases. Herein, we use ligand- and structure-based drug design approaches for identifying novel amino-pyrazine inhibitors of DLK/LZK. DN-1289 (<b>14</b>), a potent and selective dual DLK/LZK inhibitor, demonstrated excellent in vivo plasma half-life across species and is anticipated to freely penetrate the central nervous system with no brain impairment based on in vivo rodent pharmacokinetic studies and human in vitro transporter data. Proximal target engagement and disease relevant pathway biomarkers were also favorably regulated in an in vivo model of amyotrophic lateral sclerosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Craig</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><Suffix>2nd</Suffix><Identifier Source="ORCID">0000-0002-2435-1564</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Brian M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Cheng</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lexa</LastName><ForeName>Katrina W</ForeName><Initials>KW</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osipov</LastName><ForeName>Maksim</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thottumkara</LastName><ForeName>Arun P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larhammar</LastName><ForeName>Martin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-1547-6760</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyamoto</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rana</LastName><ForeName>Anil</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kane</LastName><ForeName>Lesley A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yulyaningsih</LastName><ForeName>Ernie</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-2110-2017</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solanoy</LastName><ForeName>Hilda</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Hoang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chau</LastName><ForeName>Roni</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Earr</LastName><ForeName>Timothy</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kajiwara</LastName><ForeName>Yuji</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-9307-8215</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fleck</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lucas</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haddick</LastName><ForeName>Patrick C G</ForeName><Initials>PCG</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Ryan H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Canet</LastName><ForeName>Mark J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poda</LastName><ForeName>Suresh B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scearce-Levie</LastName><ForeName>Kimberly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Srivastava</LastName><ForeName>Ankita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sweeney</LastName><ForeName>Zachary K</ForeName><Initials>ZK</Initials><Identifier Source="ORCID">0000-0002-9852-1802</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Musheng</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Chemistry, WuXi AppTec Co., Ltd., 168 Nanhai Road, 10th Avenue, Tianjin TEDA, Tianjin 300457, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Chemistry, WuXi AppTec Co., Ltd., 168 Nanhai Road, 10th Avenue, Tianjin TEDA, Tianjin 300457, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Jianrong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Chemistry, WuXi AppTec Co., Ltd., 168 Nanhai Road, 10th Avenue, Tianjin TEDA, Tianjin 300457, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lei</LastName><ForeName>Yanan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Chemistry, WuXi AppTec Co., Ltd., 168 Nanhai Road, 10th Avenue, Tianjin TEDA, Tianjin 300457, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhuo</LastName><ForeName>Zheng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Chemistry, WuXi AppTec Co., Ltd., 168 Nanhai Road, 10th Avenue, Tianjin TEDA, Tianjin 300457, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Vicente</LastName><ForeName>Javier</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-2498-0843</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Chem</MedlineTA><NlmUniqueID>9716531</NlmUniqueID><ISSNLinking>0022-2623</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.11.25</RegistryNumber><NameOfSubstance UI="D020930">MAP Kinase Kinase Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016350" MajorTopicYN="N">Leucine Zippers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020930" MajorTopicYN="N">MAP Kinase Kinase Kinases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>5</Day><Hour>11</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36469401</ArticleId><ArticleId IdType="doi">10.1021/acs.jmedchem.2c01056</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>